Brief: Meiragtx To Present Clinical Data From Phase 1 Trial Of Aav-Haqp1 For Radiation-Induced Xerostomia On Tuesday, December 13, 2022
08/12/2022 21:45
Dec 8 (Reuters) -
* MEIRAGTX TO PRESENT CLINICAL DATA FROM PHASE 1 TRIAL OF
AAV-HAQP1 FOR RADIATION-INDUCED XEROSTOMIA ON TUESDAY, DECEMBER
13, 2022
Source text for Eikon: ID:nGNX20mXFw
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on MeiraGTx Holdings
See all newsU.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
MeiraGTx gains; reports over $200 mln in license revenue
MeiraGTx Holdings PLC reports results for the quarter ended June 30 - Earnings Summary
MeiraGTx Q2 revenue jumps on Reogen license revenue
Brief: Graviton Bioscience Announces Clearance Of Investigational New Drug For GV101 For Treatment Of Friedreich's Ataxia